Teleflex is separating into two publicly traded companies to optimize growth and shareholder value. The acquisition of Biotronik's Vascular Intervention expands Teleflex's presence in coronary and ...

New, independent, publicly traded company (NewCo) consisting of Teleflex’s Urology, Acute Care, and OEM businesses. RemainCo will consist of Teleflex’s Vascular Access, Interventional ...

Teleflex to create a new, independent publicly traded company (“NewCo”) consisting of Teleflex’s Urology, Acute Care, and OEM businesses. Teleflex RemainCo (“RemainCo”) will consist of ...

Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak ...

WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has entered into a definitive agreement to ...

(Bloomberg) -- Teleflex Inc. is in discussions to acquire German medical technology firm Biotronik SE & Co.’s vascular intervention unit, according to people familiar with the matter. Teleflex ...

Throughout the last three months, 4 analysts have evaluated Teleflex TFX, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their recent ...

WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial ...

TFX opened at $132.58 on Friday. Teleflex has a fifty-two week low of $130.60 and a fifty-two week high of $249.90. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a ...

Teleflex announced a major strategic pivot, planning to separate into two independent publicly traded companies to maximize shareholder value. The separation, expected to complete by mid-2026 ...